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Abstract
Objective To compare risks of cardiovascular
outcomes between patients with type 2 diabetes and
patients with established coronary heart disease.
Design Cross sectional study and cohort study using
routinely collected datasets.
Setting Tayside, Scotland (population 400 000) during
1988›95.
Subjects In the cross sectional study, among patients
aged 45›64, 1155 with type 2 diabetes were compared
with 1347 who had had a myocardial infarction in the
preceding 8 years. In the cohort study 3477 patients
of all ages with newly diagnosed type 2 diabetes were
compared with 7414 patients who had just had a
myocardial infarction.
Main outcome measures Risk ratios for death from
all causes, cardiovascular death, and hospital
admission for myocardial infarction were calculated
by Cox proportional hazards analysis and adjusted for
age and sex.
Results In the cross sectional study the adjusted risk
ratio for death from all causes was 2.27 (95%
confidence interval 1.82 to 2.83) for patients who had
had myocardial infarction compared with those with
diabetes, and the risk ratio for hospital admission for
myocardial infarction was 1.33 (1.14 to 1.55). In the
cohort study, patients who had just had a myocardial
infarction had a higher risk of death from all causes
(adjusted risk ratio 1.35 (1.25 to 1.44)), cardiovascular
death (2.93 (2.54 to 3.41)), and hospital admission for
myocardial infarction (3.10 (2.57 to 3.73)).
Conclusions Patients with type 2 diabetes were at
lower risk of cardiovascular outcomes than patients
with established coronary heart disease.
Introduction
The increased risk of cardiovascular disease in type 2
diabetes is well recognised1 and is associated with both
diabetes specific risk factors2 and increased frequency
of conventional risk factors for cardiovascular disease.3
A recent study by Haffner et al suggested that the risk
of death from coronary heart disease in patients with
type 2 diabetes may even be as high as in patients who
have had a myocardial infarction.4 This observational
study in Finland examined the seven year incidence of
cardiovascular events among 890 patients with
diabetes who had no history of myocardial infarction
and 69 patients without diabetes who had previously
had a myocardial infarction. The risk of death from
coronary heart disease was not significantly different
between the two groups, with an adjusted hazard ratio
of 1.2 (95% confidence interval 0.6 to 2.4).
The authors of this study proposed that patients
with diabetes should be treated as if they had existing
coronary heart disease. The role of primary prevention
of coronary heart disease in patients with diabetes has
since come under much scrutiny, with some diabetolo›
gists advocating aggressive treatment of cardiovascular
risk factors. The National Cholesterol Education
Program and the American Diabetes Association have
recommended lower goals for low density lipoprotein
cholesterol both in patients with coronary heart
disease and in those with diabetes.5 However, others
argue that treatment decisions should not be based on
individual risk factors in isolation.6
An important weakness of Haffner et al’s study was
the lack of power to detect differences between the two
groups. Other larger studies have found a high risk of
cardiovascular disease for patients with diabetes, but
one lower than that for patients with coronary heart
disease.7 Haffner et al’s patients were also a self selected
group in that they represented the 80% of eligible sub›
jects who attended a clinic visit for the study.
The aim of the present investigation was to
compare risks of cardiovascular outcomes between
patients with diabetes and patients with established
coronary heart disease. We carried out two studies: in
the first we used a design similar to that of Haffner et
al,4 and in the second we compared patients with newly
diagnosed diabetes for cardiovascular risk with those
who had just had a myocardial infarction.
Subjects and methods
Data sources
We carried out the work with the DARTS/MEMO Col›
laboration using routine data sources for the
population of Tayside, Scotland, which can be record
linked using a unique patient identifier.8 9 These
include a register of all patients with type 1 and type 2
diabetes in Tayside from 1988 (which has been
validated and shown to have high sensitivity and
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specificity for the diagnosis of diabetes9), a record of all
inpatient hospital admissions in Tayside from 1980
with diagnostic codes from ICD›9 (international classi›
fication of diseases, ninth revision), and records of
death certificates from the registrar general with ICD›9
coded causes of death from 1988. The study
population comprised patients who were alive and
resident in Tayside in January 1987 and who were
either still alive in Tayside at the end of the study or
who had died (thus excluding emigrants from Tayside).
Cross sectional study
We identified a cross section of patients aged 45›64
years at the study index date (1 January 1988). This was
the age range used by Haffner et al.4 We defined a dia›
betic group, which included all patients with type 2
diabetes diagnosed before the index date. Any patient
for whom a diagnosis of type 1 diabetes was not made
(that is, diagnosed at < 35 years old and requiring
insulin treatment) was judged to have type 2 diabetes.
We also defined a group of patients who had had a
myocardial infarction: all patients aged 45›64 who had
an inpatient hospital admission with myocardial
infarction (ICD›9 code 410.9) between January 1980
and December 1987. We excluded any patient who was
in both groups. Follow up was from January 1988 to
December 1995.
The outcomes were mortality (any cause), ascer›
tained from death certification records, and hospital
admission with a primary diagnosis of myocardial inf›
arction (ICD›9 410.9). We used a Cox proportional
hazards model to calculate risk ratios (with 95% confi›
dence intervals), adjusted for age and sex, for the risks
of the outcomes in the myocardial infarction group
compared with those in the diabetic group.
Cohort study
We identified two cohorts of patients. The diabetic
cohort included any patient in the study population
with type 2 diabetes diagnosed between January 1988
and December 1995. Their study index date was their
date of diagnosis of diabetes. The myocardial infarction
cohort included any patient who had a first hospital
admission with a primary or secondary diagnosis of
myocardial infarction (ICD›9 410.9) between January
1988 and December 1995. Their study index date was
their date of hospital admission. Any patient in either
cohort who had a hospital admission for myocardial
infarction between January 1980 and December 1987
was excluded from the study, as were patients with type
2 diabetes diagnosed on the same day as their first
myocardial infarction.
The outcomes in this study during follow up to
December 1995 were mortality (any cause), cardiovas›
cular mortality (with the underlying cause of death
recorded on the death certificate coded as a cardiovas›
cular death), and hospital admission for myocardial
infarction (any hospital admission with a primary or
secondary diagnosis code of 410.9). Any patient who
died within 28 days after their index date was excluded
from further analyses. This was to eliminate deaths that
were due directly to the myocardial infarction. We con›
structed Kaplan›Meier survival curves to compare
probability of death between the study cohorts. We
used a Cox proportional hazards model to compare
the risks, with adjustment for age and sex.
Results
Our study population consisted of 263 175 patients.
Cross sectional study
We identified 1155 patients (42% women) with
diabetes, with a mean age of 57 years and a mean
duration of diabetes of 6.04 years. We identified 1347
patients (28% women) with myocardial infarction, with
a mean age of 57 and a mean time since infarction of
3.5 years.
In the eight year follow up 438 (32.5%) of the
patients in the myocardial infarction group died, and
274 (20.3%) were hospitalised for a further infarction.
In the diabetic group 284 (24.6%) died, and 113 (9.8%)
were hospitalised for an infarction. The adjusted risk
ratio for mortality in the myocardial infarction group
compared with the diabetic group was 1.33 (95% con›
fidence interval 1.14 to 1.55), while that for hospital
admission for myocardial infarction was 2.27 (1.82 to
2.83) (table 1). The risks of these outcomes seemed to
be greater for men than women, and the risks
increased with age (although age was a weaker predic›
tor of hospital admission for myocardial infarction
than of death).
Cohort study
For the diabetic cohort, we identified 3477 patients
(49% women), with a mean age of 66, of whom 3403
(98%) were included in the statistical analyses (patients
who did not die within 28 days after their index date).
For the myocardial infarction cohort, we identified
7414 patients (46% women), with a mean age of 71, of
whom 5350 (72%) were included in the statistical
analyses.
Table 1 Risk of death from all causes and hospital admission for myocardial infarction
in cross sectional study of patients with type 2 diabetes and those who had had a
myocardial infarction
Diabetic group MI group
Risk ratio (95% CI)*
No of
patients
No of
events
No of
patients
No of
events
Death from all causes
Age (years):
45›49 102 8 106 23 0.34 (0.24 to 0.49)
50›54 260 39 237 60 0.48 (0.38 to 0.59)
55›59 299 68 366 100 0.61 (0.51 to 0.73)
60›64 494 169 638 255 1.00
Sex:
Men 668 182 974 334 1.35 (1.15 to 1.61)
Women 487 102 373 104 1.00
Diagnosis:
MI — — 1347 438 1.33 (1.14 to 1.55)
Diabetes 1155 284 — — 1.00
Hospital admission for myocardial infarction
Age (years):
45›49 102 5 106 22 0.71 (0.47 to 1.06)
50›54 260 19 237 50 0.81 (0.61 to 1.06)
55›59 299 27 366 75 0.85 (0.67 to 1.08)
60›64 497 62 638 127 1.00
Sex:
Men 668 71 974 208 1.28 (1.03 to 1.61)
Women 487 42 373 66 1.00
Diagnosis:
MI — — 1347 274 2.27 (1.82 to 2.83)
Diabetes 1155 113 — — 1.00
MI=myocardial infarction.
*Adjusted for all covariates, derived from Cox regression analysis.
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During the subsequent follow up, there were 1196
deaths in the diabetic cohort (35.1% of the patients in
the analyses), of which 222 were cardiovascular deaths,
and 142 patients were hospitalised for myocardial inf›
arction. In the myocardial infarction cohort there were
2596 deaths (48.8% of patients in the analyses), of
which 1077 were cardiovascular deaths, and 656
patients were hospitalised for myocardial infarction.
The Kaplan›Meier survival curves show that the
diabetic cohort had lower risks for death from all
causes (fig 1), cardiovascular deaths (fig 2), and
hospitalisation for myocardial infarction (fig 3). The
reduced risk seemed to be mainly in the early period of
follow up, with the gradients of the curves converging
after the first 1000 days or so.
Table 2 indicates that patients in the myocardial
infarction cohort had an increased risk of death from
any cause compared with patients in the diabetic
cohort, with an adjusted risk ratio of 1.35 (95%
confidence interval 1.25 to 1.44). The risk increased
with age, and men were at greater risk than women
(adjusted risk ratio 1.19 (1.12 to 1.26)). Patients in the
myocardial infarction cohort had a threefold higher
risk of death from a cardiovascular cause than patients
in the diabetic cohort (adjusted risk ratio 2.93 (2.54 to
3.41)), and the risk of cardiovascular death increased
with age, but there was no difference between men and
women. The myocardial infarction cohort also had an
increased risk of hospital admission for myocardial inf›
arction (adjusted risk ratio 3.10 (2.57 to 3.73)). The
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Fig 1 Kaplan›Meier survival curve showing time to death from any
cause in patients with newly diagnosed type 2 diabetes and patients
who had just had a myocardial infarction (MI)
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Fig 2 Kaplan›Meier survival curve showing time to death from
cardiovascular causes in patients with newly diagnosed type 2
diabetes and patients who had just had a myocardial infarction (MI)
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Fig 3 Kaplan›Meier survival curve showing time to hospital
admission for myocardial infarction in patients with newly diagnosed
type 2 diabetes and patients who had just had a myocardial
infarction (MI)
Table 2 Risk of death from all causes, death from cardiovascular causes, and hospital
admission for myocardial infarction in cohort study of patients with newly diagnosed
type 2 diabetes and those who had just had a myocardial infarction
Diabetic group MI group
Risk ratio (95% CI)*
No of
patients
No of
events
No of
patients
No of
events
Death from all causes
Age (years):
<50 441 30 397 41 0.05 (0.04 to 0.07)
50›59 677 92 870 191 0.12 (0.10 to 0.13)
60›69 1005 295 1457 548 0.25 (0.23 to 0.27)
70›79 840 434 1565 920 0.51 (0.47 to 0.55)
>79 440 345 1061 896 1.00
Sex:
Men 1734 604 3062 1352 1.19 (1.12 to 1.26)
Women 1669 592 2288 1244 1.00
Diagnosis:
MI — — 5350 2596 1.35 (1.25 to 1.44)
Diabetes 3403 1196 — — 1.00
Death from cardiovascular causes
Age (years):
<50 441 6 397 17 0.10 (0.07 to 0.16)
50›59 677 12 870 86 0.22 (0.18 to 0.27)
60›69 1005 61 1457 235 0.42 (0.36 to 0.48)
70›79 840 87 1565 389 0.70 (0.61 to 0.80)
>79 440 56 1061 350 1.00
Sex:
Men 1734 113 3062 559 1.07 (0.95 to 1.19)
Women 1669 109 2288 518 1.00
Diagnosis:
MI — — 5350 1077 2.93 (2.54 to 3.41)
Diabetes 3403 222 — — 1.00
Hospital admission for myocardial infarction
Age (years):
<50 441 11 397 48 1.18 (0.85 to 1.62)
50›59 677 20 870 106 1.25 (0.96 to 1.62)
60›69 1005 49 1457 213 1.61 (1.28 to 1.99)
70›79 840 50 1565 189 1.41 (1.13 to 1.75)
>79 440 12 1061 100 1.00
Sex:
Men 1734 69 3062 385 1.00 (0.87 to 1.15)
Women 1669 73 2288 271 1.00
Diagnosis:
MI — — 5350 656 3.10 (2.57 to 3.73)
Diabetes 3403 142 — — 1.00
MI=myocardial infarction.
*Adjusted for all covariates, derived from Cox regression analysis.
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risks of hospital admission were higher in the age
groups 60›69 and 70›79 than in the group aged >80,
but there was no difference between men and women.
Discussion
We found that patients with type 2 diabetes were at
lower risk of death from all causes, death from cardio›
vascular causes, and hospital admission for myocardial
infarction than patients with established coronary
heart disease. Thus, our results do not support the
hypothesis that patients with diabetes have as high a
cardiovascular risk as patients with established
coronary heart disease.
Although routine data sources should always be
used cautiously,10 the inpatient hospital admissions
data and mortality data that we used were derived from
nationally collected datasets, a previous study showed
that ICD›9 coding for myocardial infarction was accu›
rate in Tayside,11 and the diabetes register, which has
complete population based coverage, has been well
used and validated.9
Comparison with other studies
For our cross sectional study, we used a design similar
to that used by Haffner et al in their Finnish study.4 The
patient groups were slightly different in that we
included patients whose diabetes was treated by diet
only (not included in the Finnish study), and patients in
the myocardial infarction group were restricted to
those whose myocardial infarction occurred in the
preceding eight years. Patients in the myocardial
infarction group were clearly at an increased risk of
death and hospital admission for myocardial infarc›
tion, after adjustment for the differences in age and sex
between the two groups. Although we were unable to
adjust for differences in cardiovascular risk factors at
baseline (smoking status, hypertension, low density and
high density lipoprotein cholesterol concentrations,
and total cholesterol and triglyceride concentrations),
such adjustments in the Finnish study reduced the haz›
ard ratio for death from coronary heart disease only
slightly, from 1.4 (95% confidence interval 0.7 to 2.6) to
1.2 (0.6 to 2.4). In our study a substantial decrease
would be required for the difference in risk of hospital
admission for myocardial infarction to be no longer
significant. An important point is the narrow width of
the confidence intervals in our study.
Although we could not make a direct comparison
between the results from the two studies, as we were
unable to determine mortality from coronary heart
disease in our patient groups, it is interesting that the
result for overall mortality in our study falls within the
confidence interval for mortality from coronary heart
disease in the Finnish study. We believe that our study
highlights the lack of power in the earlier study. It also
shows that the cardiovascular risk profile is clearly dif›
ferent in patients with diabetes compared with those
who have had a myocardial infarction.
Another concern with the Finnish study was its
cross sectional design. Patients were recruited into the
study on the basis of existing diabetes (mean duration
eight years) and previous myocardial infarction (mean
time since infarction not given).4 It is possible that the
rates of cardiovascular disease in the two groups varies
with time since diagnosis of diabetes and time since
myocardial infarction. Our second study therefore
compared rates between patients with newly diagnosed
diabetes and those who had just had a myocardial inf›
arction. This comparison may have more clinical
relevance. Again, the results showed higher risks of
death from all causes, cardiovascular deaths, and
hospital admission for myocardial infarction in
patients who had had a myocardial infarction
compared with patients with diabetes.
Implications of results
Our results have important implications for clinical
practice, in that we should be cautious about basing
treatment decisions on individual risk factors for
cardiovascular disease in isolation, as Byrne and Wild
have discussed in more detail.6
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